Literature DB >> 18424696

Cutting edge: Enhanced IL-2 signaling can convert self-specific T cell response from tolerance to autoimmunity.

Jason Waithman1, Thomas Gebhardt, Gayle M Davey, William R Heath, Francis R Carbone.   

Abstract

Naive and memory T cells show differences in their response to antigenic stimulation. We examined whether this difference extended to the peripheral deletion of T cells reactive to self-Ag or, alternatively, the induction of autoimmunity. Our results show that although both populations where susceptible to deletion, memory T cells, but not naive T cells, also gave rise to autoimmunity after in vivo presentation of skin-derived self-Ags. The same migratory dendritic cells presented self-Ag to both naive and memory T cell populations, but only the latter had significant levels of the effector molecule granzyme B. Memory T cells also expressed increased levels of the high affinity IL-2 receptor chain after self-Ag recognition. Provision of IL-2 signaling using a stimulatory complex of anti-IL-2 Ab and IL-2 drove the otherwise tolerant naive T cells toward an autoimmune response. Therefore, enhanced IL-2 signaling can act as a major selector between tolerance and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424696     DOI: 10.4049/jimmunol.180.9.5789

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8⁺ T cells.

Authors:  Andreas Kupz; Greta Guarda; Thomas Gebhardt; Leif E Sander; Kirsty R Short; Dimitri A Diavatopoulos; Odilia L C Wijburg; Hanwei Cao; Jason C Waithman; Weisan Chen; Daniel Fernandez-Ruiz; Paul G Whitney; William R Heath; Roy Curtiss; Jürg Tschopp; Richard A Strugnell; Sammy Bedoui
Journal:  Nat Immunol       Date:  2012-01-08       Impact factor: 25.606

Review 2.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

Authors:  Thomas R Malek; Iris Castro
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

3.  FOXO3 is differentially required for CD8+ T-cell death during tolerance versus immunity.

Authors:  Mayura V Wagle; Ian A Parish
Journal:  Immunol Cell Biol       Date:  2016-06-21       Impact factor: 5.126

4.  A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Authors:  Salvatore Fiorenza; Tony J Kenna; Iain Comerford; Shaun McColl; Raymond J Steptoe; Graham R Leggatt; Ian H Frazer
Journal:  J Immunol       Date:  2012-11-09       Impact factor: 5.422

Review 5.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

6.  CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function.

Authors:  Laura Rivino; Paola Gruarin; Barbara Häringer; Svenja Steinfelder; Laura Lozza; Bodo Steckel; Anja Weick; Elisa Sugliano; David Jarrossay; Anja A Kühl; Christoph Loddenkemper; Sergio Abrignani; Federica Sallusto; Antonio Lanzavecchia; Jens Geginat
Journal:  J Exp Med       Date:  2010-03-01       Impact factor: 14.307

7.  IL-2 mediates CD4+ T cell help in the breakdown of memory-like CD8+ T cell tolerance under lymphopenic conditions.

Authors:  Cécile Le Saout; Marine Villard; Clémence Cabasse; Chantal Jacquet; Naomi Taylor; Javier Hernandez
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

8.  The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice.

Authors:  Calliope A Dendrou; Linda S Wicker
Journal:  J Clin Immunol       Date:  2008-09-09       Impact factor: 8.317

9.  Langerhans cells are not required for the CD8 T cell response to epidermal self-antigens.

Authors:  Laura S Bursch; Benjamin E Rich; Kristin A Hogquist
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  ESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo.

Authors:  Andreas Kupz; Ulrike Zedler; Manuela Stäber; Carolina Perdomo; Anca Dorhoi; Roland Brosch; Stefan H E Kaufmann
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.